Department of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece
Volume 28, Issue 4, December 2017
Sign in to download the Issue in PDF format.
1576580691
Mediterr J Rheumatol 2017;28(4):210-1
Article Links
A new player in psoriatic arthritis: a JAK inhibitor
References
- Sakkas L I, Alexiou I, Simopoulou T, Vlychou M. Enthesitis in psoriatic arthritis. Semin Arthritis Rheum 2013;43:325-34.
- Matthew A J, Bird P, Gupta A, George R E, Danda D. Magnetic resonance imaging (MRI) of the feet demonstrates subclinical inflammatory disease in cutaneous psoriasis patients without clinical arthritis. Ann Rheum Dis 2017;76:727.
- Sakkas L I, Bogdanos D P. Are psoriasis and psoriatic arthritis the same disease? The Il-23/IL-17 axis data. Autoimmune Rev 2017;16:10-5.
- Gossec L, Smolen J S, Ramiro S, de Wit M, Cutolo M, Dougados M, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016;75:499-510.
- Coates L C, Kavanaugh A, Mease P J, Soriano E R, Laura Acosta-Felquer M, Armstrong A W, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol 2016;68:1060-71.
- Mease P, Hall S, FitzGerald O, van der Heijde D, Merola J F, Avila-Zapata F, et al. Tofacinib versus adalimumab in psoriatic arthritis. New Engl J Med 2017;377:1537-50.
- Gladman D, Rigby W, Azevedo V F, Behrens F, Blanco R, Kaszuba A, et al. Tofacitinib for psoriatic arthritis in patients with inadequate response to TNF inhibitors. New Engl J Med 2017;377:1525-36.
- Ghoreschi K, Laurence A, O’Shea J J. Janus kinases in immune cell signaling. Immunol Rev 2009;228:273-87.
- Richlin C, Rahman P, Kavanaugh A, McInnes I B, Puig L, Li S, et al. Efficacy and safety of the anti-IL-12/23 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapry:6-month, and 1-year results of the phase 3, multicenter, double-blind, placebo-controlled, randomized PSUMMIT 2 trial. Ann Rheum Dis 2014;73:990-9.
- Kavanaugh A, McInnes I B, Mease P J, Hall S, Chinoy H, Kivitz A J, et al. Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: Results from the randomized placebo-controlled FUTURE 2 study. J Rheumatol 2016;43:1713-7.